Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;64(3):433-435.
doi: 10.1111/ajd.14067. Epub 2023 Apr 27.

Treatment of severe, refractory pyoderma gangrenosum with infliximab, adalimumab and intravenous immunoglobulin

Zachary Holmes  1 , Jacqueline Nguyen  1 , Ashling Courtney  2 , Dale Jobson  1   2 , Robert Kelly  1
Affiliations

Treatment of severe, refractory pyoderma gangrenosum with infliximab, adalimumab and intravenous immunoglobulin

Zachary Holmes et al. Australas J Dermatol. 2023 Aug.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505-9.
    1. Yamasaki K, Yamanaka K, Zhao Y, Iwano S, Takei K, Suzuki K, et al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: final analysis of a 52-week phase 3 open-label study. J Dermatol. 2022;49(5):479-87.
    1. Herberger K, Dissemond J, Brüggestrat S, Sorbe C, Augustin M. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges. 2018;17(1):32-41.
    1. Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J. 2019;16(2):511-21.
    1. Agarwal A, Andrews J. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38(6):563-72.

MeSH terms

LinkOut - more resources